Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y, Kawashima Y, Chiba S, Hara S, Yamazaki Y, Doman T, Saito S, Odaka T, Ogasawara T, Shimizu H, Sugisaka J, Aiba T, Toi Y, Yamanda S, Kimura Y, Sugawara S. Murakami Y, et al. Among authors: kawashima y. Cancer Rep (Hoboken). 2024 Feb;7(2):e1981. doi: 10.1002/cnr2.1981. Epub 2024 Jan 11. Cancer Rep (Hoboken). 2024. PMID: 38212894 Free PMC article.
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Kawashima Y, et al. Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28. Respir Investig. 2014. PMID: 24853020 Clinical Trial.
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. Among authors: kawashima y. Oncologist. 2018 Nov;23(11):1358-1365. doi: 10.1634/theoncologist.2017-0384. Epub 2018 Jun 22. Oncologist. 2018. PMID: 29934411 Free PMC article.
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. Among authors: kawashima y. JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860. JAMA Oncol. 2019. PMID: 30589930 Free PMC article.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R, Ogasawara T, Tsurumi K, Ono K, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Aso M, et al. Among authors: kawashima y. Oncologist. 2020 Mar;25(3):e536-e544. doi: 10.1634/theoncologist.2019-0550. Epub 2019 Nov 7. Oncologist. 2020. PMID: 32162801 Free PMC article.
Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
Toi Y, Kimura Y, Domeki Y, Kawana S, Aiba T, Ono H, Aso M, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Saito R, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Honda Y, Sugawara S. Toi Y, et al. Among authors: kawashima y. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):74-78. doi: 10.36141/svdld.v36i1.7383. Epub 2019 May 1. Sarcoidosis Vasc Diffuse Lung Dis. 2019. PMID: 32476938 Free PMC article.
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
Kawashima Y, Harada T, Fujita Y, Nakagawa T, Watanabe K, Morikawa N, Takamura K, Kanazawa K, Kuda T, Usui K, Sekine A, Inoue A, Sugawara S. Kawashima Y, et al. Int J Clin Oncol. 2021 Mar;26(3):515-522. doi: 10.1007/s10147-020-01828-1. Epub 2020 Nov 13. Int J Clin Oncol. 2021. PMID: 33184754 Clinical Trial.
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Sugisaka J, Toi Y, Taguri M, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Sugisaka J, et al. Among authors: kawashima y. JMA J. 2020 Jan 15;3(1):58-66. doi: 10.31662/jmaj.2019-0005. Epub 2019 Nov 8. JMA J. 2020. PMID: 33324776 Free PMC article.
2,119 results